NCT06885762

Efgartigimod for the Treatment of Guillain-Barré Syndrome

Safety and Efficacy of Efgartigimod in Guillain-Barré Syndrome

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Zhongming Qiu · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluating the efficacy and safety of efgartigimod in the treatment of Guillain-Barré Syndrome and exploring the immunological mechanisms of efgartigimod therapy in Guillain-Barré Syndrome. The main questions it aims to answer are: Will efgartigimod improve the symptoms of participants? What medical problems do participants have when using efgartigimod? Participants will: On day 1 and day 5 of the treatment period, drug A was administered intravenously. Keep a diary of their symptoms

Conditions

• Guillain-Barre Syndrome (GBS)

Interventions

Type	Name	Description
DRUG	efgartigimod	efgartigimod 20 mg/kg was administered via intravenous infusion on day 1 and day 5 of the treatment period only.

Timeline

• Start date: 2025-04-13
• Primary completion: 2026-06-30
• Completion: 2026-12-31
• First posted: 2025-03-20
• Last updated: 2025-03-20

Regulatory

• FDA-regulated drug study